Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015 · Active, not recruiting

Last updated 2026-05-28

This clinical trial tests how long-acting GLP-1 or a combination of GLP-1 and GIP affects stomach emptying in people with obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-10 · est. completion 2028-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06801015 ↗

Description as written by the study sponsor.

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

Treatments tested

Semaglutide Drug

Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
Tirzepatide Drug

Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
Placebo Drug

Placebo administered by subcutaneous injection once per week.

Main thing measured	Gastric emptying of solids T1/2 min, that is time for half meal to empty from stomach
Sponsor	Mayo Clinic
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06801015 ↗